Gilead Sciences Korea said it has signed a memorandum of understanding to designate two Korean hospitals -- Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC) – as Gilead HOPE (Hematology-Oncology Portfolio Engagement Site) institutions to collaborate on developing new oncology drugs.

Gilead has been collaborating with top research centers worldwide, involving them in early to late-stage clinical trials.

Under the MOU, Gilead plans to expand its pipeline in the field of oncology and attract more global clinical trials to Korea, in line with its corporate strategy.

"This agreement will enhance access to global clinical trials in oncology for Korean patients, advancing local medical science," SNUH Clinical Trials Center Director Kim Dong-wan said. "We are eager to accelerate the development of new cancer drugs with Gilead, contributing to significant changes in patients' lives."

SMC Research Vice President Lee Kyu-sung said, "By providing patients with various clinical trial opportunities through this agreement with Gilead, we expect to address unmet medical needs in the healthcare field."

Lee added that SMC is committed to conducting high-standard clinical trials to improve the treatment landscape in Korea.

Gilead Sciences Korea expressed its excitement regarding the MOU.

"Seoul consistently ranks first in the number of clinical trial registrations globally, reflecting its excellent capabilities and environment," Gilead Sciences Korea General Manager Choi Jae-yeon said. "Gilead Sciences Korea prioritizes attracting clinical trials for new drugs to meet the needs of patients in Korea and advance local medical science."

She went on to say, “Gilead is thrilled to partner with these globally recognized institutions, hoping this collaboration will bring more innovative cancer treatments and healthier futures for patients.”